Abstract
Background: The combination of Pertuzumab (PER) + Trastuzumab (HER) + Docetaxel (DTX) triple combination was established as the primary treatment of HER2 positive advanced and recurrent breast cancer. High tumor shrinkage effect was observed. So, to prevent side effects such as neurotoxicity by DTX, there are cases of transition to PER + HER maintenance therapy. Relapse was observed during PER + HER maintenance therapy, and DTX re-administration was performed in 4 cases, so we report it.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
